Decoy Therapeutics to Showcase Peptide Therapeutics at Boston Conferences
Decoy Therapeutics, a preclinical-stage biotechnology company, will present at two peptide therapeutics conferences in Boston. The company will discuss its Designable Multi-Antivirals (D-MAVs) platform, which uses proprietary peptide conjugates to target shared viral mechanisms. Chief Business Officer Peter Marschel will lead a roundtable on computational peptide design, while Chief Scientific Officer Dr. Barbara Hibner and Chief Technology Officer Dr. Michael Lipp will present on peptide conjugate antiviral therapeutics. The presentations will highlight Decoy's strategic partnership with Quantori and its AI-driven peptide design platform. 
